Drugs / Insulin glargine U100
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03766854 | Dec 2018 → Dec 2019 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03922750 Comparator | May → Dec 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06767735 Comparator | Feb 2025 → Aug 2026 overdue | diabetes mellitus | Gan & Lee Pharmaceuticals. | Active not recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-01-08 | Novo Nordisk A/S | COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes novonordisk.com ↗ |
| 2022-06-03 | Novo Nordisk A/S | Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1 novonordisk.com ↗ |
| 2016-11-29 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial novonordisk.com ↗ |
| 2016-02-23 | Novo Nordisk A/S | Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes novonordisk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin glargine U100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03922750 ↗ |
| Known as | IGlar U100 | “once-daily insulin glargine 100 units/mL (IGlar U100)” PMID 33875485 ↗ Apr 2021 |
| Modality | Protein / enzyme biologic | “once-daily insulin glargine 100 units/mL (IGlar U100)” PMID 33875485 ↗ Apr 2021 |
| Route | Subcutaneous | “Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks” NCT03766854 ↗ |